Charles Schwab Investment Management Inc Lexicon Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,144,632 shares of LXRX stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,144,632
Previous 883,227
29.6%
Holding current value
$1.63 Million
Previous $839,000
88.2%
% of portfolio
0.0%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
227MCall Options Held
2.5MPut Options Held
271K-
Artal Group S.A. Luxembourg, N4136MShares$193 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$55.3 Million2.06% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.52MShares$13.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.83MShares$5.44 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $268M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...